These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 4830223)

  • 21. Complement activation in semi-solid medium: Insolubilization of properdin and the third component of complement (C3) in agar gels.
    Ziegler JB; Watson L; Goodkofsky I; Alper CA; Lepow IH
    J Immunol; 1976 Jan; 116(1):75-9. PubMed ID: 812917
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decreased synthesis of the third component of complement (C3) in hypocomplementemic systemic lupus erythematosus.
    Sliwinski AJ; Zvaifler NJ
    Clin Exp Immunol; 1972 May; 11(1):21-9. PubMed ID: 5038771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic polymorphism in human glycine-rich beta-glycoprotein.
    Alper CA; Boenisch T; Watson L
    J Exp Med; 1972 Jan; 135(1):68-80. PubMed ID: 4109808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The reaction of zymosan with the properdin system in normal and C4-deficienct guinea pig serum. Demonstration of C3- and C5-cleaving multi-unit enzymes, both containing factor B, and acceleration of their formation by the classical complement pathway.
    Brade V; Lee GD; Nicholson A; Shin HS; Mayer MM
    J Immunol; 1973 Nov; 111(5):1389-400. PubMed ID: 4795621
    [No Abstract]   [Full Text] [Related]  

  • 25. Evidence for glomerular modulation of complement activation.
    Moseley HL; Whaley K
    J Clin Lab Immunol; 1979 Apr; 2(1):9-13. PubMed ID: 95813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.
    Whaley K; Schur PH; Ruddy S
    J Clin Invest; 1976 Jun; 57(6):1554-63. PubMed ID: 819459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolism of C3 and factor B in patients with congenital factor I deficiency.
    Rasmussen JM; Teisner B; Brandt J; Brandslund I; Gry H
    J Clin Lab Immunol; 1990 Feb; 31(2):59-67. PubMed ID: 1966986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro synthesis of factor B of the alternative pathway of complement activation by mouse peritoneal macrophages.
    Bentley C; Bitter-Suermann D; Hadding U; Brade V
    Eur J Immunol; 1976 Jun; 6(6):393-8. PubMed ID: 1033069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of C3b in the breakdown of C3 in hypocomplementaemic mesangiocapillary glomerulonephritis.
    Williams DG; Lachmann PJ; Charlesworth JA; Peters DK
    Lancet; 1973 Mar; 1(7801):447-9. PubMed ID: 4120364
    [No Abstract]   [Full Text] [Related]  

  • 30. Relative importance of C3b inactivator and beta 1H globulin in the modulation of the properdin amplification loop in systemic lupus erythematosus.
    Whaley K; Schur PH; Ruddy S
    Clin Exp Immunol; 1979 Jun; 36(3):408-14. PubMed ID: 114347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.
    Mayes JT; Schreiber RD; Cooper NR
    J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Studies on the properdin system: isolation of a heat-labile factor from guinea pig serum related to a human glycine rich beta-glycoprotein (GBG or factor B).
    Brade V; Cook CT; Shin HS; Mayer MM
    J Immunol; 1972 Dec; 109(6):1174-81. PubMed ID: 4628703
    [No Abstract]   [Full Text] [Related]  

  • 33. Homozygous human C3 deficiency. The role of C3 in antibody production, C-1s-induced vasopermeability, and cobra venom-induced passive hemolysis.
    Alper CA; Colten HR; Gear JS; Rabson AR; Rosen FS
    J Clin Invest; 1976 Jan; 57(1):222-9. PubMed ID: 1107355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. C3 metabolism in ulcerative colitis and Crohn's disease.
    Hodgson HJ; Potter BJ; Jewell DP
    Clin Exp Immunol; 1977 Jun; 28(3):490-5. PubMed ID: 891024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute local inflammation alters synthesis, distribution, and catabolism of third component of complement (C3) in rabbits.
    Manthei U; Strunk RC; Giclas PC
    J Clin Invest; 1984 Aug; 74(2):424-33. PubMed ID: 6746901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complement depletion accelerates the clearance of immune complexes from the circulation of primates.
    Waxman FJ; Hebert LA; Cornacoff JB; VanAman ME; Smead WL; Kraut EH; Birmingham DJ; Taguiam JM
    J Clin Invest; 1984 Oct; 74(4):1329-40. PubMed ID: 6480828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.
    Perrin LH; Lambert PH; Miescher PA
    J Clin Invest; 1975 Jul; 56(1):165-76. PubMed ID: 1141431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative analyses of the relationship between C3 consumption, C3b capture, and immune adherence of complement-fixing antibody/DNA immune complexes.
    Edberg JC; Tosic L; Wright EL; Sutherland WM; Taylor RP
    J Immunol; 1988 Dec; 141(12):4258-65. PubMed ID: 3198918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolism of properdin in normal subjects and patients with renal disease.
    Ziegler JB; Rosen FS; Alper CA; Grupe W; Lepow IH
    J Clin Invest; 1975 Sep; 56(3):761-7. PubMed ID: 1159085
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alper CA, Rosen FS: Studies of the in vivo behavior of human C'3 in normal subjects and patients.
    Alper CA; Rosen FS
    J Clin Invest; 1967 Dec; 46(12):2021-34. PubMed ID: 6074005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.